Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Corcept Therapeutics Incorporated, Pliant Therapeutics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Corcept Therapeutics Incorporated, Pliant Therapeutics and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Corcept Therapeutics Incorporated, Pliant Therapeutics and Inc.

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig’s disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company’s lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Latest Pharmaceuticals and Corcept Therapeutics Incorporated, Pliant Therapeutics, Inc. Stock News

As of July 31, 2026, Corcept Therapeutics Incorporated had a $12.4 billion market capitalization, compared to the Pharmaceuticals median of $579.1 million. Corcept Therapeutics Incorporated’s stock is up 229% in 2026, up 20.1% in the previous five trading days and up 63.77% in the past year.

Currently, Corcept Therapeutics Incorporated’s price-earnings ratio is 252.2. Corcept Therapeutics Incorporated’s trailing 12-month revenue is $830.8 million with a 6.6% net profit margin. Year-over-year quarterly sales growth most recently was 31.7%. Analysts expect adjusted earnings to reach $2.280 per share for the current fiscal year. Corcept Therapeutics Incorporated does not currently pay a dividend.

As of July 31, 2026, Pliant Therapeutics, Inc. had a $64.4 million market cap, putting it in the 18th percentile of all stocks. Pliant Therapeutics, Inc.’s stock is down 14.8% in 2026, down 4.6% in the previous five trading days and down 31.58% in the past year.

Currently, Pliant Therapeutics, Inc. does not have a price-earnings ratio. Pliant Therapeutics, Inc.’s trailing 12-month revenue is $0.0 million with a % net profit margin. As of July 31, 2026, Pliant Therapeutics, Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-1.410 per share for the current fiscal year. Pliant Therapeutics, Inc. does not currently pay a dividend.

How We Compare Corcept Therapeutics Incorporated, Pliant Therapeutics and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Corcept Therapeutics Incorporated, Pliant Therapeutics and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Corcept Therapeutics Incorporated, Pliant Therapeutics and Inc. Growth Grades

Company	Ticker	Growth
Corcept Therapeutics Incorporated	CORT	A
Pliant Therapeutics, Inc.	PLRX	na

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Corcept Therapeutics Incorporated has a Growth Score of 89, which is Very Strong. Pliant Therapeutics, Inc. does not have a meaningful Growth Score.

The Growth Stock Winner: Undetermined

If you are strictly a growth investor, you may want to add Corcept Therapeutics Incorporated to your watch list. However, because only one of the companies in this comparison has a valid Growth Grade, we cannot call it a clear winner. Evaluation of the other grades for both companies is necessary in order to understand which stock is the better investment based on AAII’s proprietary scores and analysis.

Corcept Therapeutics Incorporated, Pliant Therapeutics and Inc.’s Momentum Grades

Company	Ticker	Momentum
Corcept Therapeutics Incorporated	CORT	A
Pliant Therapeutics, Inc.	PLRX	D

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Corcept Therapeutics Incorporated has a Momentum Score of 98, which is Very Strong. Pliant Therapeutics, Inc. has a Momentum Score of 21, which is Weak.

The Momentum Grade Winner: Corcept Therapeutics Incorporated

As you can clearly see from the Momentum Grade breakdown above, Corcept Therapeutics Incorporated is considered to have stronger momentum compared to Pliant Therapeutics, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Corcept Therapeutics Incorporated could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Corcept Therapeutics Incorporated, Pliant Therapeutics and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Corcept Therapeutics Incorporated	CORT	B
Pliant Therapeutics, Inc.	PLRX	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Corcept Therapeutics Incorporated has a Earnings Estimate Score of 78, which is Positive. Pliant Therapeutics, Inc. has a Earnings Estimate Score of 53, which is Neutral.

The Earnings Estimate Revisions Grade Winner: Corcept Therapeutics Incorporated

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Corcept Therapeutics Incorporated has a better Earnings Estimate Revisions Grade than Pliant Therapeutics, Inc.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Corcept Therapeutics Incorporated could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Corcept Therapeutics Incorporated, Pliant Therapeutics and Inc. Grades

In addition to Growth, Momentum and Estimate Revisions, A+ Investor also provides grades for Value and Quality.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Corcept Therapeutics Incorporated, Pliant Therapeutics and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Corcept Therapeutics Incorporated, Pliant Therapeutics or Inc. Stock?

Overall, Corcept Therapeutics Incorporated stock has a Growth Score of 89, Momentum Score of 98 and Estimate Revisions Score of 78.

Pliant Therapeutics, Inc. stock has a Growth Score of , Momentum Score of 21 and Estimate Revisions Score of 53.

Comparing Corcept Therapeutics Incorporated, Pliant Therapeutics and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.